MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings

被引:88
作者
Dutoit J.C. [1 ]
Verstraete K.L. [1 ]
机构
[1] Department of Radiology, MR -1K12, Ghent University Hospital, De Pintelaan 185, Ghent
关键词
Diffusion weighted imaging; Dynamic contrast-enhanced MRI; Magnetic resonance imaging; Multiple myeloma; Response assessment;
D O I
10.1007/s13244-016-0492-7
中图分类号
学科分类号
摘要
Magnetic resonance imaging (MRI) is increasingly being used in the diagnostic work-up of patients with multiple myeloma. Since 2014, MRI findings are included in the new diagnostic criteria proposed by the International Myeloma Working Group. Patients with smouldering myeloma presenting with more than one unequivocal focal lesion in the bone marrow on MRI are considered having symptomatic myeloma requiring treatment, regardless of the presence of lytic bone lesions. However, bone marrow evaluation with MRI offers more than only morphological information regarding the detection of focal lesions in patients with MM. The overall performance of MRI is enhanced by applying dynamic contrast-enhanced MRI and diffusion weighted imaging sequences, providing additional functional information on bone marrow vascularization and cellularity. This pictorial review provides an overview of the most important imaging findings in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma, by performing a ‘total’ MRI investigation with implications for the diagnosis, staging and response assessment. Main message • Conventional MRI diagnoses multiple myeloma by assessing the infiltration pattern. • Dynamic contrast-enhanced MRI diagnoses multiple myeloma by assessing vascularization and perfusion. • Diffusion weighted imaging evaluates bone marrow composition and cellularity in multiple myeloma. • Combined morphological and functional MRI provides optimal bone marrow assessment for staging. • Combined morphological and functional MRI is of considerable value in treatment follow-up. © 2016, The Author(s).
引用
收藏
页码:553 / 569
页数:16
相关论文
共 52 条
[1]
Nanni C., Rubello D., Fanti S., Et al., Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer, Biomed Pharmacother, 60, pp. 409-413, (2006)
[2]
Kyle R.A., Durie B.G., Rajkumar S.V., Et al., Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management, Leukemia, 24, pp. 1121-1127, (2010)
[3]
Smith D., Yong K., Multiple myeloma, BMJ, 346, (2013)
[4]
Rajkumar S.V., Dimopoulos M.A., Palumbo A., Et al., International myeloma working group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, 15, pp. e538-e548, (2014)
[5]
Rajkumar S.V., Myeloma today: disease definitions and treatment advances, Am J Hematol, 91, pp. 90-100, (2016)
[6]
Pratt G., Bowcock S., Chantry A., Et al., Time to redefine myeloma, Br J Haematol, 171, pp. 1-10, (2015)
[7]
Dimopoulos M.A., Hillengass J., Usmani S., Et al., Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement, J Clin Oncol, 33, pp. 657-664, (2015)
[8]
Hillengass J., Landgren O., Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma, Leuk Lymphoma, 54, pp. 1355-1363, (2013)
[9]
Hillengass J., Fechtner K., Weber M.A., Et al., Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma, J Clin Oncol, 28, pp. 1606-1610, (2010)
[10]
Padhani A.R., Khan A.A., Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy, Target Oncol, 5, pp. 39-52, (2010)